Vivesto ABOSTO:VIVE -3.40%26 PB Ratio is 0.56 as of Jul. 03, 2026, which is 62% below its 10-year median of 1.47. GuruFocus rates OSTO:VIVE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Vivesto AB ranks better than 90.55% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-03), Vivesto AB's share price is kr8.404. Vivesto AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr15.04. Hence, Vivesto AB's PB Ratio of today is 0.56.
Warning Sign:
Vivesto AB stock PB Ratio (=0.57) is close to 2-year high of 0.57.
The historical rank and industry rank for Vivesto AB's PB Ratio or its related term are showing as below:
OSTO:VIVE'
s PB Ratio Range Over the Past 10 Years
Min: 0.17 Med: 1.47 Max: 7.4
Current: 0.55
During the past 13 years, Vivesto AB's highest PB Ratio was 7.40. The lowest was 0.17. And the median was 1.47.
OSTO:VIVE's PB Ratio is ranked better than 90.55% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs OSTO:VIVE: 0.55
During the past 12 months, Vivesto AB's average Book Value Per Share Growth Rate was -38.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -27.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -35.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -20.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vivesto AB was 43.80% per year. The lowest was -41.40% per year. And the median was -6.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vivesto AB PB Ratio Related Terms
Vivesto AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Vivesto AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vivesto AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vivesto AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vivesto AB (OSTO:VIVE) has a PB Ratio of 0.56 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivesto AB and its competitors. This is 62% below median its historical median of 1.47. Over the past decade, Vivesto AB's PB Ratio has ranged from 0.17 to 7.40. According to the industry distribution chart, Vivesto AB ranks #87 out of 921 companies in the Drug Manufacturers industry, placing it in the top 9.4%.
Is Vivesto AB's PB Ratio too high?
Vivesto AB's current PB Ratio of 0.56 is 62% below median its 10-year median of 1.47. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 7.40. The Drug Manufacturers industry median PB Ratio is 1.91. Vivesto AB's value of 0.56 is 70.7% below this industry median. Based on the distribution chart, Vivesto AB ranks #87 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #87 out of 921 companies for PB Ratio. This places Vivesto AB in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.91. Vivesto AB's value of 0.56 is 70.7% below this benchmark. Historically, Vivesto AB's own PB Ratio has ranged from 0.17 to 7.40 over the past decade. While the company's 10-year median is 1.47 vs. the industry median of 1.91, Vivesto AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivesto AB's current PB Ratio of 0.56 is 70.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current PB Ratio is 0.56, which is 62% below median its own 10-year median of 1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current PB Ratio of 0.56. The current PB Ratio is 0.56, which is 62% below median its 10-year median of 1.47 and 70.7% below the Drug Manufacturers industry median of 1.91. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current PB Ratio is 0.56 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OSTO:VIVE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VIVE has been successfully added to your 
